Zymergen Inc.
Case Number:
1:23-bk-11661
Court:
Nature of Suit:
Firms
- Buchalter APC
- Chipman Brown
- Connolly Gallagher
- Cross & Simon
- Faegre Drinker
- Felderstein Fitzgerald
- Goodwin Procter
- Landis Rath
- Lowenstein Sandler
- Margolis Edelstein
- Mayer Brown
- Monzack Mersky
- Morgan Lewis
- Morris Nichols
- Pachulski Stang
- Porzio Bromberg
- Potter Anderson
- Robbins Geller
- Saul Ewing
- Simpson Thacher
- Sullivan & Cromwell
- Troutman Pepper
- Young Conaway
Companies
- Chilmark Partners LLC
- Fortis Advisors LLC
- Intrepid Investment Bankers
- JPMorgan Chase & Co.
- Lazard Ltd.
- Lighthouse eDiscovery Inc.
- Oracle Corp.
- Pivot Bio Inc.
- The Cigna Group
- The Goldman Sachs Group Inc.
- Zymergen Inc.
Sectors & Industries:
-
February 05, 2024
Zymergen Ch. 11 Plan Confirmed After Investor Objection
Biotechnology company Zymergen received confirmation of its Chapter 11 plan Monday at a hearing in Delaware bankruptcy court after resolving an objection to the plan from a class of investors suing the company.
-
December 19, 2023
Zymergen Gets Conditional OK For Ch. 11 Asset Sales
A Delaware bankruptcy judge on Tuesday signaled she would approve biotechnology company Zymergen's asset sales to two bidders as part of its Chapter 11 liquidation plan, under an agreement whereby the debtor's parent will acquire most of the business.
-
December 15, 2023
Zymergen Names 2 Successful Bidders In Ch. 11 Auction
Biotechnology company Zymergen notified a Delaware bankruptcy judge this week it received two successful bids in its Chapter 11 auction, one bid coming from its corporate parent, Ginkgo Bioworks, and the other from sustainable agriculture business Pivot Bio Inc.
-
November 14, 2023
Del. Judge OKs Bidding Procedures In Zymergen Ch. 11
A Delaware bankruptcy judge has approved bidding procedures for the sale of Zymergen's assets, including a stalking horse agreement from its corporate parent Gingko Bioworks, after the biotechnology company reached a resolution with objecting unsecured creditors.
-
October 25, 2023
US Trustee Balks At 5% Breakup Fee In Zymergen Bid
The Office of the U.S. Trustee objected to the proposed bidding procedures in Zymergen Inc.'s Chapter 11 case, telling a Delaware bankruptcy court that the 5% breakup fee to be paid to the biotech's parent company and stalking horse bidder isn't justified.
-
October 12, 2023
Meet The Attorneys For Biotech Biz Zymergen In Its Ch. 11
Attorneys from Morris Nichols Arsht & Tunnell LLP are representing Zymergen Inc. in its Chapter 11 in Delaware as the biotechnology company pursues an asset sale with a $5 million stalking horse offer in place.
-
October 04, 2023
Zymergen Files Liquidation Plan As Ch. 11 Case Begins In Del.
Biotechnology company Zymergen Inc. filed a plan of liquidation Wednesday describing proposed treatment of creditor classes as the company kicked off its Chapter 11 case with a first-day hearing in Delaware bankruptcy court.
-
October 03, 2023
Biotech Co. Zymergen Hits Ch. 11 In Del. Eyeing Asset Sale
Biotechnology company Zymergen Inc. on Tuesday filed for Chapter 11 protection in Delaware with both assets and debts of $100 million to $500 million, saying it's seeking an asset sale and aiming to collate securities claims tied to a sharp drop in its share price following a 2021 initial public offering.